A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Avexitide in Participants With Post-Bariatric Hypoglycemia

AVX-001 (LUCIDITY) is a Phase 3 study to evaluate avexitide compared to placebo in participants with post bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass (RYGB). The study will assess avexitide compared to placebo for safety and efficacy, measured by reduction of hypoglycemic events. The study includes a Screening period with a Run-in period (of up to 6- and 3-weeks, respectively); a randomized, double-blind, placebo-controlled study treatment period of 16 weeks; and a two-part open-label extension (OLE) period with a duration of approximately 32 weeks.

开始日期2025-04-29

申办/合作机构

Amylyx Pharmaceuticals, Inc.

NCT06498063

/ Unknown statusN/AIIT

Renal Extraction of Glucagon and Renal Effects of Glucagon

The goal of this crossover study is to investigate to what extend glucagon affects the kidneys. The main questions it aims to answer are:
Does glucagon regulate kidney function through extraction in the kidney in addition to glomerular filtration? Does glucagon regulate kidney function by increasing renal plasma flow and glomerular filtration rate? Does glucagon regulate kidney function by increasing renal salt excretion?

开始日期2024-02-20

申办/合作机构

Bispebjerg Hospital

[+3]

ACTRN12614001117606

/ Recruiting临床4期IIT

Defining the role of endogenous glucagon-like peptide-1 (GLP-1) in the glycaemic, triglyceride and energy expenditure responses to fat in patients with Type 2 Diabetes (T2D) using Galvus (vildagliptin) and the GLP-1 receptor antagonist exendin (9-39)

开始日期2016-04-01

申办/合作机构-

100 项与 Avexitide 相关的临床结果

登录后查看更多信息

100 项与 Avexitide 相关的转化医学

登录后查看更多信息

100 项与 Avexitide 相关的专利（医药）

登录后查看更多信息

318

项与 Avexitide 相关的文献（医药）

2026-08-01·Molecular Metabolism

Dysregulated glucagon signaling contributes to hypoglycemia after vertical sleeve gastrectomy in mice

Article

作者: McClennan, Andrew ; Bethea, Maigen ; Benninger, Richard Kp ; Cook, Tyler M ; Birznieks, Carissa ; da Silva Teixeira, Silvania ; Patti, Mary-Elizabeth ; Sandoval, Darleen A ; Hendrix, Jasmine

OBJECTIVES:

After bariatric surgery, many individuals experience debilitating bouts of hypoglycemia, termed post-bariatric hypoglycemia (PBH). Our mouse model of vertical sleeve gastrectomy (VSG) mimics key aspects of PBH in humans. As glucagon is a key element of the counterregulatory hormonal response to hypoglycemia, the objective of this manuscript is to understand if glucagon responses and sensitivity are altered after VSG in mice.

METHODS:

Mice underwent sham or VSG surgery. We measured glucagon responses to insulin-induced hypoglycemia and mixed meal tolerance tests. We then measured glucose and insulin responses to different doses of exogenous glucagon in fed and fasted states. Lastly, we performed in vitro experiments to examine glucagon responses to glucose and amino acids.

RESULTS:

Postprandial glucagon levels were elevated in mice after VSG, but glucose responses to low doses of exogenous glucagon were blunted in the fasted and postprandial state. Administration of low dose glucagon in the fed state led to hypoglycemia in some VSG mice in parallel with stimulation of insulin release. This effect was partially prevented by pretreatment with the GLP-1 receptor antagonist exendin9-39. In islets isolated from VSG mice, glucagon release in response to high glucose was suppressed, but glucagon responses to alanine and high glucose were not different compared to sham controls.

CONCLUSIONS:

Altogether, our data suggest both glucagon responses, and sensitivity to exogenous glucagon are altered by VSG. The glucagon dysregulation was not observed in isolated islets suggesting gut signaling may be critical in driving glucagon responses after VSG.

2026-08-01·JOURNAL OF ETHNOPHARMACOLOGY

Yueju pill exerts rapid antidepressant effects via sequential activation of hippocampal GLP-1 receptor and PACAP signaling in mice

Article

作者: Han, Mingzhi ; Xie, Huijun ; Chen, Gang ; Wu, Changyu ; Wang, Yanqin ; Zhang, Hailou ; Peng, Yuhan ; Xing, Shan

ETHNOPHARMACOLOGICAL RELEVANCE:

Yueju pill (YJ), a classical Chinese medicine formula first documented in 'Danxixinfa by Zhu Danxi for treating "six stagnations" (Liu Yu: qi, blood, phlegm, fire, dampness, and food), has been clinically prescribed for mood disorders characterized by qi stagnation and depression for centuries. Despite its historical application for relieving emotional constraint (Yujie) and treating depressive disorders, the rapid antidepressant mechanism and molecular targets of YJ remain incompletely elucidated.

AIM OF THE STUDY:

This study aimed to investigate the rapid antidepressant-like effects of YJ and uncover the underlying mechanism involving hippocampal GLP-1 receptor (GLP-1r) and pituitary adenylate cyclase-activating polypeptide (PACAP) signaling.

MATERIALS AND METHODS:

The chemical stability of YJ was evaluated by quantifying active constituents. A chronic unpredictable mild stress (CUMS) mouse model was employed to assess rapid antidepressant effects of YJ through acute administration using behavioral paradigms including novelty-suppressed feeding (NSF), tail suspension (TST), forced swim (FST), and sucrose preference tests (SPT). Hippocampal transcriptome sequencing was performed 30 min post-treatment to identify key targets. Protein and gene expressions were validated by Western blot, immunofluorescence, and quantitative PCR. Pharmacological interventions using exendin (9-39) (GLP-1r antagonist) and PACAP6-38 (PACAP antagonist) were conducted to establish signaling hierarchies. Additionally, HT22 hippocampal neuronal cells were utilized to examine direct effects on synaptic proteins.

RESULTS:

Four active constituents (shanzhiside methylester, geniposide, ferulic acid, and gentiobioside) were identified in YJ with stable and reproducible concentrations. Acute administration of YJ (2 g/kg, as the final extract) rapidly ameliorated depressive-like behaviors in CUMS mice, with effects comparable to ketamine. Hippocampal transcriptome sequencing identified 461 differentially expressed genes following YJ treatment, with GLP-1r and Adcyap1 (PACAP) notably upregulated compared to the CUMS group. Western blot, immunofluorescence and PCR confirmed that YJ elevated protein and gene expression of GLP-1r and PACAP in the dentate gyrus within 30 min. Pharmacological blockade of GLP-1r with exendin9-39 abolished YJ's rapid antidepressant effects and prevented YJ-induced PACAP upregulation. Conversely, intra-dentate gyrus injection of PACAP6-38 blocked YJ's behavioral effects without affecting GLP-1 expression, indicating that PACAP acts downstream of GLP-1. In HT22 cells, YJ dose-dependently upregulated GLP-1r and PACAP, while also improving synaptic protein expression (pCaMKII, synapsin-1, PSD95, and BDNF).

CONCLUSION:

These findings demonstrate that YJ produces rapid antidepressant effects through activation of hippocampal GLP-1r-dependent PACAP signaling, providing scientific evidence for the traditional "resolving depression" (Jieyu) function of this classical formula and identifying a novel polyherbal strategy for rapid-acting antidepressant therapy.

2026-07-01·JOURNAL OF ETHNOPHARMACOLOGY

Dendrobium huoshanense polysaccharides alleviate DSS-induced ulcerative colitis in mice: comparison between different parts of plant and role of GLP-1/GLP-1R axis

Article

作者: Luo, Jian-Ping ; Li, Qiang-Ming ; Zha, Xue-Qiang ; Shang, Zhen-Zi ; Zhang, Feng-Yun ; Gao, Xin

ETHNOPHARMACOLOGICAL RELEVANCE:

Dendrobium huoshanense has been long used to treat gastrointestinal disorders including ulcerative colitis (UC) in traditional Chinese medicine. Polysaccharides as its main active components can alleviate UC by reducing inflammation, and promote the secretion of glucagon-like peptide-1 (GLP-1), which possesses anti-inflammatory effects via GLP-1 receptor (GLP-1R). However, it remains unclear whether polysaccharides from different parts of this herb are equally effective in alleviating UC and whether polysaccharides function via GLP-1/GLP-1R axis.

AIM OF THE STUDY:

To identify the part in which the polysaccharide is most effective in alleviating UC and to explore its mechanism of action through GLP-1/GLP-1R axis.

MATERIALS AND METHODS:

The physicochemical properties of polysaccharides were analyzed. A dextran sulfate sodium (DSS)-induced UC mouse model was used to assess colitis-associated damage via morphological scoring, histopathological evaluation and inflammatory examination with multi-cytokine array and western blotting. Gut microbiota compositions, short-chain fatty acid contents and GLP-1 levels were measured, and their roles were checked using antibiotic mixture and GLP-1R antagonist Exendin (9-39).

RESULTS:

Stem, leaf and flower polysaccharides, with different molecular weight, monosaccharide composition and spatial conformation, differentially alleviated UC symptoms, and stem polysaccharide (DHPS) showed the strongest efficacy, as evidenced by improved epithelial integrity, mucus barrier and inflammatory disorder. DHPS-alleviated UC was independent of DHPS-altered gut microbiota and positively correlated with DHPS-elevated GLP-1 levels, which could be abolished by Exendin (9-39), suggesting that GLP-1-activated GLP-1R signaling mediated the effects of DHPS against UC.

CONCLUSIONS:

DHPS is the most effective polysaccharide for alleviating DSS-induced UC through GLP-1/GLP-1R axis, proposing DHPS is a valid candidate for UC treatment using D. huoshanense.

项与 Avexitide 相关的新闻（医药）

2026-09-01

·微信

速递 | 反向玩转GLP-1！avexitide大幅降低55%术后严重低血糖

整理 | GLP1减重宝典内容团队当整个行业都在挖掘GLP‑1受体激动剂在减重、降糖领域的巨大价值时，一款作用逻辑完全相反的在研药物，凭借Ⅲ期临床亮眼数据走进大众视野。它不去激活GLP‑1受体，反而主动阻断该靶点信号，用来解决减重手术之后出现的反复严重低血糖难题，为代谢药物研发打开截然不同的思考方向。减重手术是现阶段重度肥胖重要的治疗手段，Roux‑en‑Y胃旁路术凭借出色的减重与代谢改善效果，在全球范围内得到广泛应用，但手术带来的消化道重构，也会让一小部分患者面临长期并发症风险，减重术后低血糖，也就是PBH，便是其中棘手的一类问题。部分患者在完成胃旁路手术数月甚至数年之后，每次进食过后，身体肠道L细胞会大量释放GLP‑1，远超普通人进食后的激素分泌水平，过度刺激胰岛β细胞分泌胰岛素。直接带来的后果就是餐后血糖先冲高，随后快速大幅回落，诱发低血糖发作。这类低血糖存在明确的等级划分，2级属于具备临床意义的低血糖，患者会出现心慌、手抖、出冷汗、头晕、注意力涣散等一系列表现；发展到3级也就是严重低血糖阶段，患者会发生意识混乱、抽搐、失去意识，往往需要旁人介入救助，日常工作出行都将受到明显限制，生活质量大打折扣。从临床现状来看，目前美国还没有专门针对减重术后低血糖的获批药物，患者只能依靠少食多餐、规避精制碳水这类饮食方案，搭配持续血糖监测进行管控。临床医生偶尔会超适应症使用其他类型药物，但治疗效果个体差异很大，始终缺少可以直击发病根源的靶向治疗选项。 Amylyx Pharmaceuticals推进的LUCIDITYⅢ期临床试验，正是为验证avexitide对于这类患者的实际治疗价值。该研究属于多中心、随机、双盲、安慰剂对照试验，一共纳入78名成年受试者，全部都接受过Roux‑en‑Y胃旁路手术，并且已经确诊减重术后低血糖。受试者按照3比2的比例分组，分别每日皮下注射90mg的avexitide或者安慰剂，持续开展16周双盲治疗周期，试验同时还设置了后续32周开放标签延展阶段，用来继续观察长期用药安全性表现。此次公布的顶线数据显示，试验顺利达成和FDA共同确认的主要终点，对比安慰剂组别，avexitide治疗组2级与3级低血糖复合事件的发生率实现55%的相对下降，统计结果具备极高显著性，p值为0.000003。这里需要厘清概念，55%代表的是事件发生频率的相对降幅，并不代表有55%的受试患者病症被彻底治愈。除此之外，这项研究全部次要终点同样顺利达标，无论是患者指尖自我血糖监测数据，还是动态CGM持续血糖采集记录，都可以看到avexitide组别各类低血糖发作频次出现一致性下降，其中高危的3级严重低血糖事件同样得到显著改善。 Avexitide属于全球首创的GLP‑1受体拮抗剂，分子本源来自吉拉毒蜥毒液多肽的截短片段，和司美格鲁肽、替尔泊肽这类热门减重降糖药物，在靶点作用逻辑上完全对立。我们熟知的GLP‑1减重药物属于受体激动剂，相当于踩下通路的油门，放大GLP‑1生理效应，以此抑制食欲、促进胰岛素分泌实现控糖减重。而avexitide会竞争性结合胰岛β细胞表面的GLP‑1受体，阻挡体内过量生成的内源GLP‑1发挥作用，抑制机体不受控的胰岛素过量释放，把餐后剧烈波动的血糖拉回相对平稳区间，从发病源头缓解术后低血糖问题。基于该药物的临床潜力，FDA此前已经授予avexitide突破性疗法认定、孤儿药资格，同时还拿到针对先天性高胰岛素血症的罕见儿科疾病认定，足以看出监管机构对于这条逆向开发路径的重视程度。从安全性反馈来看，本次Ⅲ期试验当中avexitide整体耐受性表现良好，多数不良事件程度偏轻到中等，集中在注射部位局部反应、腹泻等类型，试验期间没有出现和药物直接相关的严重不良事件，用药16周周期之内受试者体重也没有发生明显变化。按照Amylyx对外披露的规划，企业计划在2026年底之前向FDA递交avexitide的新药上市申请。如果后续完整数据集可以支撑申报，且审评流程推进顺利，avexitide有望成为全球第一款专门用于减重术后低血糖的靶向治疗药物，填补该领域长期的药物空白。但需要反复强调，截至当前avexitide依旧属于研究阶段药物，还没有获得任何地区药监机构批准上市，本次对外披露的也只是Ⅲ期顶线结果，完整详细研究数据还待后续对外公布，距离真正落地临床使用，依旧还要走完数据整理、申报、审评的整套流程。这款药物的Ⅲ期阳性结果，也给整个GLP‑1赛道带来很有价值的行业启示。大众舆论普遍形成一种固有印象，GLP‑1信号越强效果越好，提升激素活性就能实现减重降糖收益，但LUCIDITY研究清晰展示，同一条代谢通路，在不同疾病场景下，治疗方向可以截然相反。面对肥胖与2型糖尿病，医疗手段需要放大GLP‑1通路活性；可当患者经历特定减重手术，身体出现GLP‑1信号异常亢进时，治疗思路就切换为阻断受体活性，压制过度的生理反应。靶点药物开发从来不是简单的单向增强，人体代谢系统存在精密的平衡关系，部分通路过度激活，同样会诱发各类病症。avexitide的开发历程，正是精准医疗理念的鲜活案例，它提醒行业研究者，看待热门靶点不能只盯着单一治疗方向，正视病理环境的差异，反向挖掘靶点拮抗价值，同样有机会挖掘出具备重大临床价值的全新药物。而随着减重手术在全球应用规模持续扩大，减重术后低血糖的患者群体规模也在不断增长，倘若avexitide顺利获批，除了服务现有患者之外，也会带动医学界进一步关注减重手术的远期代谢并发症管理，推动相关诊疗规范持续完善。 *本文仅供医疗卫生专业人士参考版权声明：所有「GLP1减重宝典」的原创文章，转载须联系授权，并在文首/文末注明来源、作者、微信ID，否则减重宝典将向其追究法律责任。部分文章推送时未能与原作者或公众号平台取得联系。若涉及版权问题，敬请原作者联系我们。合作事宜，请添加微信：andyxu365 加入专家库与我们深度讨论 ▂▂▂▂▂ 「GLP-1俱乐部」覆盖数百位专业人士，构建了围绕GLP-1产业链上下游、覆盖多个板块的专家库，成为了业内顶尖专业人士获取行业真知灼见的首要选择。加入专家库请添加下方「运营负责人」微信，并提供名片和必要的个人信息。

2026-08-31

·微信

上市申请已递交FDA！小分子达最高4.35亿美元交易；潜在“first-in-class”多肽疗法达3期主要终点……

上市申请已递交FDA！口服小分子达成最高4.35亿美元交易 LEO Pharma宣布，已与Tanabe Pharma达成协议，将收购dersimelagon的全球权益。Dersimelagon是一款每日口服一次的小分子黑皮质素1受体（MC1R）激动剂，正在开发用于治疗红细胞生成性原卟啉症（EPP）和X连锁原卟啉症（XLP）。这两种疾病均为罕见且严重的遗传性疾病，可导致由阳光诱发的严重皮肤损伤，显著限制患者的户外活动。患者可能出现皮疹、肿胀、发红和灼烧感等症状，部分患者还可能发生肝损伤。Dersimelagon旨在增加皮肤中的黑色素，从而减少阳光穿透，并降低光毒性反应。该药已完成3期临床开发，并已于2026年6月向美国FDA提交新药申请（NDA）并进入审评。此次交易将进一步扩充LEO Pharma的罕见皮肤病研发管线。根据协议，LEO Pharma将以最高4.35亿美元的首付款及近期里程碑付款获得dersimelagon的全球权益，此外还将支付潜在的后续里程碑付款等款项。此前，LEO Pharma还完成了对Replay公司的收购，并与勃林格殷格翰（Boehringer Ingelheim）围绕Spevigo（spesolimab）开展合作。潜在“first-in-class”多肽疗法达3期主要终点！预计年内递交上市申请 Amylyx Pharmaceuticals宣布，评估其在研多肽疗法avexitide治疗减重手术后低血糖（PBH）的3期LUCIDITY临床试验取得积极顶线结果。LUCIDITY是一项多中心、随机、双盲、安慰剂对照研究，共纳入78例接受Roux-en-Y胃旁路术（RYGB）后出现PBH的受试者。研究达到与美国FDA商定的主要终点：与安慰剂相比，avexitide使2级和3级低血糖事件复合发生率降低55%（p=0.000003）。此外，研究还达到全部次要终点，包括通过自我血糖监测（SMBG）评估的2级低血糖事件、通过连续血糖监测（CGM）评估的2级低血糖事件，以及3级低血糖事件均显著减少，且结果具有高度统计学显著性和临床意义。安全性方面，avexitide总体耐受性良好，并表现出良好的安全性特征。Amylyx计划于今年年底前向FDA提交avexitide的NDA。 Avexitide是一款在研、潜在“first-in-class”的胰高血糖素样肽-1（GLP-1）受体拮抗剂，此前已在6项PBH临床试验中接受评估，同时也被用于先天性高胰岛素血症（HI）的研究。PBH患者通常存在过度增强的GLP-1反应，从而引发胰岛素过量分泌，并导致反复发生低血糖。Avexitide是一种竞争性GLP-1受体拮抗剂，旨在与胰岛β细胞上的GLP-1受体结合，抑制PBH中由GLP-1驱动的过度胰岛素反应，从而减少不适当的胰岛素分泌并稳定血糖水平。目前，FDA已授予avexitide用于PBH和先天性HI的突破性疗法认定，以及用于高胰岛素性低血糖（包括PBH和先天性HI）的孤儿药资格。最高4.9亿美元！一款罕见病小分子达成收购协议 BioMarin Pharmaceutical宣布，已与Alesta Therapeutics达成最终协议，将收购后者以获得其核心临床阶段资产ALE1。根据协议，BioMarin将支付2.75亿美元首付款，并根据后续开发和监管里程碑的达成情况支付最高2.15亿美元的额外款项。交易已获得双方董事会批准，预计将在本季度完成。在交易完成前，Alesta将把除ALE1之外的所有资产剥离至一家新实体，原Alesta员工也将转入该实体。交易完成后，ALE1项目将纳入BioMarin的骨骼疾病业务部门。 ALE1是一款口服小分子药物，正在开发用于治疗低磷酸酯酶症（HPP）。HPP是一种由ALPL基因突变引起的罕见遗传性骨病，可影响骨骼和牙齿矿化，导致易发生骨折、牙齿过早脱落，并可能使成年患者出现明显的肌无力、疲劳和疼痛。ALE1目前正在一项1/2a期临床试验中接受评估，研究对象包括健康志愿者和成年HPP患者，主要考察其安全性、耐受性以及药代动力学/药效学特征。根据新闻稿，如果获批，ALE1有望成为首款治疗HPP的口服疗法，并通过靶向该疾病的核心代谢物无机焦磷酸盐（PPi），系统性纠正疾病生物学异常，从而有望改善HPP的骨骼及其他疾病表现。参考资料： [1] Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia. Retrieved August 18, 2026 from https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-announces-positive-topline-results-0 [2] LEO Pharma further strengthens late-stage pipeline with the acquisition of dersimelagon. Retrieved August 18, 2026 from https://leo-pharma.com/media-center/news/leo-pharma-further-strengthens-late-stage-pipeline-with-the-acquisition-of-dersimelagon/ [3] BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline. Retrieved August 18, 2026 from https://www.prnewswire.com/news-releases/biomarin-to-acquire-alesta-therapeutics-to-gain-ale1-a-potential-first-oral-therapy-for-hypophosphatasia-adding-an-important-clinical-program-to-biomarins-pipeline-302854068.html 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，传递医学新知

2026-08-31

·药研苑

朱养心药业止吐外用药物格拉司琼透皮贴片首仿上市获批

药品营销避坑”试读：药品导入期管理视频课（试听）药品生命周期管理（案例）药品立项需要注意什么（案例） 2026年8月27日国家药品监督管理局（NMPA）网站信息显示，杭州朱养心药业格拉司琼透皮贴片的仿制上市申请已获得NMPA批准。格拉司琼（Granisetron）为选择性5-羟色胺3（5-HT₃）受体拮抗剂透皮贴片，能够抑制5-HT作用于5-HT₃受体引起的呕吐反应。国内获批的剂型包括注射剂、片剂、口崩片和透皮贴片。2018年协和麒麟（kyowa kirin）的格拉司琼透皮贴片（善可舒）在国内获批上市，单片最多可以使用7天，适应症为：用于预防需要接受连续 3-5 天的中度和/或高度致吐性化疗引起的恶心和呕吐。善可舒上市后由于价格昂贵和未进入医保，市场表现一般。杭州朱养心药业是国内第一家获批格拉司琼透皮贴片上市的仿制企业。除格拉司琼透皮贴片外，国内获批的长效止吐剂还包括帕洛诺司琼（Palonosetron），以及含帕洛诺司琼和NK-1R拮抗剂组成的复方制剂（奈妥匹坦帕洛诺司琼和磷奈匹坦帕洛诺司琼）。推荐指数：★ 推荐原因：格拉司琼透皮贴片在使用习惯上不如帕洛诺司琼口服和注射给药，疗效不帕洛诺司琼和NK-1R拮抗剂组成的复方制剂，并且还要解决医保支付问题，面临的挑战不小。个人观点，仅限参考。相关阅读：石药EGFR ADC（SYS6010）EGFR突变NSCLC三期试验达到终点转移性胰腺癌生存期翻倍，FDA批准泛RAS抑制剂Daraxonrasib Rezpegaldesleukin用于中重度特应性皮炎2b期研究数据发表康方生物依沃西单抗晚期胆道3期临床KO度伐利尤单抗康方依沃西用于经治EGFR突变晚期NSCLC癌三期临床研究发表邦耀生物基因编辑治疗β-地中海贫血临床试验实现脱离输血依赖艾伯维申请上市乌帕替尼口服溶液中因科技腺相关病毒载体哌普锐基申请上市用于结晶样视网膜变性 OX2R激动剂Alixorexton用于1型发作性睡病2期研究数据发表恒瑞抗帕金森病卡左双多巴改良药物HRG2010胶囊申请上市阿斯利康申请依赛弗酶α上市用于≥2岁低磷酸酯酶症 FDA批准强生尼卡利单抗用于温抗体型自身免疫性溶血性贫血诺华申请前列腺癌放射靶向药物镥[177Lu]特昔维匹肽本地化生产 Avexitide缓解胃旁路术后低血糖3期临床试验取得积极结果奥科达申请上市抗癫痫药物拉考沙胺缓释胶囊相关内容只作为药物研发的参信息。不构成任何与用药咨询有关的建议。如需发稿，您可通过在药研苑公众号下以发送信息的方式将官网或官方公众号的稿件链接和标题发送给我们。我们将择优确定是否发布。

100 项与 Avexitide 相关的药物交易

登录后查看更多信息